KV Pharmaceutical Co. CL A (KV.A) News

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

K-V Pharmaceutical Company to Present at Imperial Capital 2012 Healthcare Investor Forum

K-V Pharmaceutical Company to Present at Imperial Capital 2012 Healthcare Investor Forum PR Newswire ST. LOUIS, April 12, 2012 ST. LOUIS, April...

- Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

- Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

K-V Pharmaceutical Company to Present at Needham & Company 11th Annual Healthcare Conference

K-V Pharmaceutical Company to Present at Needham & Company 11th Annual Healthcare Conference PR Newswire ST. LOUIS, April 2, 2012 ST. LOUIS...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Amended Statement of Ownership (SC 13G/A)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A * (Rule 13d-102)     INFORMATION TO...

- Current report filing (8-K)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT...

- Confidential Treatment Order (CT ORDER)

- Amended Statement of Ownership (SC 13G/A)

    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of...

- Quarterly Report (10-Q)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 10-Q      ...

K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call

K-V Pharmaceutical Announces Updated Makena® Performance Metrics and Investor Conference Call Company to File Fiscal 2012 Third Quarter 10-Q...